CTLA4Ig Primed Donor Lymphocyte Infusion: A Novel Approach to Immunotherapy after Haploidentical Transplantation for Advanced Leukemia

Jaiswal, 2016, Biol Blood Marrow Transplant, 22, 1867, 10.1016/j.bbmt.2016.07.016 Jaiswal, 2017, Cytotherapy, 19, 531, 10.1016/j.jcyt.2016.12.006 Chen, 2011, Immunomodulatory effects induced by cytotoxic T lymphocyte antigen 4 immunoglobulin with donor peripheral blood mononuclear cell infusion in canine major histocompatibility complex-haplo-identical non-myeloablative hematopoietic cell transplantation, Cytotherapy, 13, 1269, 10.3109/14653249.2011.586997 Kean, 2006, NK cells mediate costimulation blockade-resistant rejection of allogeneic stem cells during nonmyeloablative transplantation, Am J Transplant, 6, 292, 10.1111/j.1600-6143.2005.01172.x Peng, 2013, CD86 is an activation receptor for NK cell cytotoxicity against tumor cells, PLoS One, 8, e83913, 10.1371/journal.pone.0083913 Jaiswal, 2017, T cell costimulation blockade promotes transplantation tolerance in combination with sirolimus and post-transplantation cyclophosphamide for haploidentical transplantation in children with severe aplastic anemia, Transpl Immunol, 43-44, 54, 10.1016/j.trim.2017.07.004 Jaiswal, 2018, Higher CD45RA (+) regulatory T cells in the graft improves outcome in younger patients undergoing T cell-replete haploidentical transplantation: where donor age matters, Biol Blood Marrow Transplant, 24, 2025, 10.1016/j.bbmt.2018.06.003 Cooley, 2010, Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia, Blood, 116, 2411, 10.1182/blood-2010-05-283051 Ruggeri, 1999, Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation, Blood, 94, 333, 10.1182/blood.V94.1.333.413a31_333_339 Jaiswal, 2018, Biol Blood Marrow Transplant, 24, 542, 10.1016/j.bbmt.2017.11.014 Przepiorka, 1995, 1994 Consensus conference on acute GVHD grading, Bone Marrow Transplant, 15, 825 Jagasia, 2015, National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease. I. The 2014 Diagnosis and Staging Working Group report, Biol Blood Marrow Transplant, 21, 389, 10.1016/j.bbmt.2014.12.001 Jaiswal, 2016, T cell costimulation blockade for hyperacute steroid refractory graft versus-host disease in children undergoing haploidentical transplantation, Transpl Immunol, 39, 46, 10.1016/j.trim.2016.08.009 Armand, 2012, A disease risk index for patients undergoing allogeneic stem cell transplantation, Blood, 120, 905, 10.1182/blood-2012-03-418202 Araki, 2016, Allogeneic hematopoietic cell transplantation for acute myeloid leukemia: time to move toward a minimal residual disease-based definition of complete remission?, J Clin Oncol, 34, 329, 10.1200/JCO.2015.63.3826 Pfeifer, 2013, Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR-ABL1-positive acute lymphoblastic leukemia, Leukemia, 27, 1254, 10.1038/leu.2012.352 Bacigalupo, 1991, Increased risk of leukemia relapse with high-dose cyclosporine A after allogeneic marrow transplantation for acute leukemia, Blood, 77, 1423, 10.1182/blood.V77.7.1423.1423 Bethge, 2004, Adoptive immunotherapy with donor lymphocyte infusions after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning, Blood, 103, 790, 10.1182/blood-2003-07-2344 Raiola, 2003, Factors predicting response and graft-versus-host disease after donor lymphocyte infusions: a study on 593 infusions, Bone Marrow Transplant, 31, 687, 10.1038/sj.bmt.1703883 Wekerle, 2000, Allogeneic bone marrow transplantation with co-stimulatory blockade induces macrochimerism and tolerance without cytoreductive host treatment, Nat Med, 6, 464, 10.1038/74731 Storb, 1999, Stable mixed hematopoietic chimerism in dogs given donor antigen, CTLA4Ig, and 100 cGy total body irradiation before and pharmacologic immunosuppression after marrow transplant, Blood, 94, 2523, 10.1182/blood.V94.7.2523.419k18_2523_2529 Miller, 2005, Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer, Blood, 105, 3051, 10.1182/blood-2004-07-2974 Russo, 2018, NK cell recovery after haploidentical HSCT with posttransplant cyclophosphamide: dynamics and clinical implications, Blood, 131, 247, 10.1182/blood-2017-05-780668 Comoli, 2001, Human alloantigen-specific anergic cells induced by a combination of CTLA4-Ig and CsA maintain anti-leukemia and anti-viral cytotoxic responses, Bone Marrow Transplant, 27, 1263, 10.1038/sj.bmt.1703063 McCurdy, 2015, Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide, Blood, 125, 3024, 10.1182/blood-2015-01-623991 Armand, 2014, Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation, Blood, 123, 3664, 10.1182/blood-2014-01-552984 Beziat, 2010, NK cell terminal differentiation: correlated stepwise decrease of NKG2A and acquisition of KIRs, PLoS One, 5, e11966, 10.1371/journal.pone.0011966 Nguyen, 2005, NK-cell reconstitution after haploidentical hematopoietic stem-cell transplantations: immaturity of NK cells and inhibitory effect of NKG2A override GvL effect, Blood, 105, 4135, 10.1182/blood-2004-10-4113 Wagner, 2017, CD56bright NK cells exhibit potent antitumor responses following IL-15 priming, J Clin Invest, 127, 4042, 10.1172/JCI90387 Dubois, 2017, IL15 infusion of cancer patients expands the subpopulation of cytotoxic CD56 (bright) NK cells and increases NK-cell cytokine release capabilities, Cancer Immunol Res, 5, 929, 10.1158/2326-6066.CIR-17-0279 Cooley, 2009, Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia, Blood, 113, 726, 10.1182/blood-2008-07-171926 Oevermann, 2014, KIR B haplotype donors confer a reduced risk for relapse after haploidentical transplantation in children with ALL, Blood, 124, 2744, 10.1182/blood-2014-03-565069 Moretta, 2002, Human NK cells and their receptors, Microbes Infect, 4, 1539, 10.1016/S1286-4579(02)00037-0 Pende, 2005, Analysis of the receptor-ligand interactions in the natural killer-mediated lysis of freshly isolated myeloid or lymphoblastic leukemias: evidence for the involvement of the Poliovirus receptor (CD155) and Nectin-2 (CD112), Blood, 105, 2066, 10.1182/blood-2004-09-3548 Pfeiffer, 2007, Intensity of HLA class I expression and KIR-mismatch determine NK-cell mediated lysis of leukaemic blasts from children with acute lymphatic leukaemia, Br J Haematol, 138, 97, 10.1111/j.1365-2141.2007.06631.x Scoville, 2018, Human AML activates the aryl hydrocarbon receptor pathway to impair NK cell development and function, Blood, 132, 1792, 10.1182/blood-2018-03-838474 Barber, 2004, LFA-1 contributes an early signal for NK cell cytotoxicity, J Immunol, 173, 3653, 10.4049/jimmunol.173.6.3653 Urlaub, 2017, LFA-1 activation in NK cells and their subsets: influence of receptors, maturation, and cytokine stimulation, J Immunol, 198, 1944, 10.4049/jimmunol.1601004